申请人:Abbott Laboratories
公开号:US05124342A1
公开(公告)日:1992-06-23
A composition for the inhibition of lipoxygenase enzymes comprising a pharmaceutically acceptable carrier and a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, arylalkenyl, reduced heteroaryl, and reduced heteroarylalkyl and substituted derivatives thereof having one or more substituents independently selected from the group consisting of halogen, alkyl, halosubstituted alkyl, aryl, arylalkyl, reduced heteroaryl, arylalkoxy, cyano, nitro, COR.sub.4, SO.sub.2 R.sub.4, NR.sub.5 R.sub.6, OR.sub.6, COCX.sub.1 X.sub.2 NR.sub.6 R.sub.7, CON(OH)R.sub.6, NR.sub.6 COR.sub.4, CR.sub.5 (NH.sub.2)CO.sub.2 R.sub.5, NHCX.sub.1 X.sub.2 CO.sub.2 R.sub.5, N(OH)CONR.sub.5 R.sub.6, N(OH)COR.sub.4, NHCONR.sub.5 R.sub.6, C(NOH)NHOH and CONHNR.sub.5 R.sub.6 ; R.sub.3 is selected from the group consisting of hydrogen, a pharmaceutically acceptable salt, COR.sub.4, COCX.sub.1 X.sub.2 NR.sub.6 R.sub.7, CR.sub.8 R.sub.9 OR.sub.10, CH.sub.2 CR.sub.8 (OR.sub.10)CH.sub.2 OR.sub.11 and SiR.sub.12 R.sub.13 R.sub.14 ; R.sub.4 is selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced heteroaryl, reduced heteroarylalkyl, OR.sub.5, NHCX.sub.1 X.sub.2 CO.sub.2 R.sub.5 and NR.sub.6 R.sub.7 ; R.sub.5 is selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, reduced heteroaryl, and reduced heteroarylalkyl; R.sub.6 and R.sub.7 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, reduced heteroaryl, reduced heteroarylalkyl and (CH.sub.2).sub.n OR.sub.5 where n is 2-4 and R.sub.5 is as defined above; R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are independently selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl and (CH.sub.2).sub.n OR.sub.5 or at least two of R.sub.8, R.sub.9, R.sub.10 and R.sub.11 together form a ring system containing 5-10 atoms wherein said ring system is carbocyclic, heterocyclic or reduced heterocyclic and R.sub.5 and n are as defined above; R.sub.12, R.sub.13 and R.sub.14 are independently selected from the group consisting of alkyl and aryl; and X.sub.1 and X.sub.2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, cycloalkyl, aryl, and arylalkyl; and the acid addition salts thereof.
一种抑制脂氧合酶酶活性的组合物,包括药学上可接受的载体和公式化合物:##STR1## 其中R.sub.1和R.sub.2分别选自由烷基,烯基,环烷基,环烯基,芳基,芳基烷基,芳基烯基,还原杂环芳基和还原杂环芳基烷基,以及其取代衍生物,其中每个取代基独立地选自卤素,烷基,卤代烷基,芳基,芳基烷基,还原杂环芳基,芳基烷氧基,氰基,硝基,COR.sub.4,SO.sub.2R.sub.4,NR.sub.5R.sub.6,OR.sub.6,COCX.sub.1X.sub.2NR.sub.6R.sub.7,CON(OH)R.sub.6,NR.sub.6COR.sub.4,CR.sub.5(NH.sub.2)CO.sub.2R.sub.5,NHCX.sub.1X.sub.2CO.sub.2R.sub.5,N(OH)CONR.sub.5R.sub.6,N(OH)COR.sub.4,NHCONR.sub.5R.sub.6,C(NOH)NHOH和CONHNR.sub.5R.sub.6;R.sub.3选自氢,药学上可接受的盐,COR.sub.4,COCX.sub.1X.sub.2NR.sub.6R.sub.7,CR.sub.8R.sub.9OR.sub.10,CH.sub.2CR.sub.8(OR.sub.10)CH.sub.2OR.sub.11和SiR.sub.12R.sub.13R.sub.14;R.sub.4选自氢,烷基,烯基,环烷基,环烯基,芳基,芳基烷基,还原杂环芳基,还原杂环芳基烷基,OR.sub.5,NHCX.sub.1X.sub.2CO.sub.2R.sub.5和NR.sub.6R.sub.7;R.sub.5选自氢,烷基,烯基,环烷基,芳基,芳基烷基,还原杂环芳基和还原杂环芳基烷基;R.sub.6和R.sub.7分别选自氢,烷基,烯基,环烷基,芳基,芳基烷基,还原杂环芳基,还原杂环芳基烷基和(CH.sub.2).sub.nOR.sub.5,其中n为2-4,R.sub.5如上所定义;R.sub.8,R.sub.9,R.sub.10和R.sub.11独立地选自氢,烷基,芳基,芳基烷基和(CH.sub.2).sub.nOR.sub.5,或者R.sub.8,R.sub.9,R.sub.10和R.sub.11中至少两个组成含5-10个原子的环系统,所述环系统为碳环,杂环或还原杂环,R.sub.5和n如上所定义;R.sub.12,R.sub.13和R.sub.14独立地选自烷基和芳基;X.sub.1和X.sub.2独立地选自氢,烷基,烯基,环烷基,芳基和芳基烷基;以及其酸加成盐。